CIDP, chronic inflammatory demyelinating polyneuropathy; IG, immune globulin; IgG, immunoglobulin G; IVIG, intravenous immunoglobulin. References GAMUNEX®-C (immune globulin injection [human], 10% caprylate/chromatography purified) Prescribing Information. Grifols. Hughes RAC, Donofrio P, Bril V, et ...
Food and Drug Administration (FDA) has approved Gamunex, an intravenous immune globulin (IVIG) pooled from human blood, for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Gamunex is the first product to receive FDA approval as an orphan drug for this neurologic disease....
In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmune 1999;13:129-35. Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc ...
静脉注射免疫球蛋白IVIG在新生儿疾病中的应用2024课件 静脉注射用免疫球蛋白外科和ICU中的抗感染应用 探究免疫球蛋白治疗 中国静脉注射免疫球蛋白(IVIg)治疗行业市场占有率及投资前景预测分析报告 中国静脉注射人免疫球蛋白行业市场占有率及投资前景预测分析报告 人免疫球蛋白 博研咨询:中国静脉注射人免疫球蛋白行业市场情况...
Home IVIG for CIDP: A Focus on Patient Centred Care. Objective: To determine the safety and tolerability of home-based intravenous immunoglobulin (IVIG) (Gamunex) as maintenance treatment in patients with chr... D Hans,Katzberg,Vilija,... - 《Canadian Journal of Neurological Sciences Le Journal...
Gamunex-C (Immune Globulin Injection (Human) 10% Caprylate/Chromatography Purified]) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.
There were no AEs in 99.3% of infusions.DiscussionLong-term treatment of CIDP patients with IVIG 10% in real-world conditions maintained clinical stability on fatigue and depression over 96 weeks. This treatment was well-tolerated and safe....
Objective: To determine the efficacy of IVIG on nerve fiber density, pain and examination scores in a double blind placebo controlled pilot study of patients with SFN associated with TS-HDS and FGFR3.Background: Small fiber neuropathies (SFN) have many potential causes but >50% remain ...